CO2018001531A2 - Lisobactina para su uso en el tratamiento de la mastitis bovina - Google Patents
Lisobactina para su uso en el tratamiento de la mastitis bovinaInfo
- Publication number
- CO2018001531A2 CO2018001531A2 CONC2018/0001531A CO2018001531A CO2018001531A2 CO 2018001531 A2 CO2018001531 A2 CO 2018001531A2 CO 2018001531 A CO2018001531 A CO 2018001531A CO 2018001531 A2 CO2018001531 A2 CO 2018001531A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- bovine mastitis
- lysobactin
- present
- bovine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención tiene por objeto proporcionar un agente para el tratamiento de la mastitis bovina que no sufra la desventaja de la resistencia bacteriana hacia el ingrediente activo. La presente invención se refiere a lisobactina para su uso en el tratamiento de la mastitis bovina. Ninguna de las técnicas previas se refiere al tratamiento de la mastitis bovina mediante el uso de lisobactina. La presente invención también se refiere a una composición farmacéutica que se formula para la administración intramamaria en las mamas bovinas, donde la composición comprende lisobactina. Preferentemente, la composición comprende adicionalmente un excipiente farmacéuticamente aceptable y en particular un portador farmacéuticamente aceptable
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15181209 | 2015-08-17 | ||
| PCT/EP2016/069380 WO2017029271A1 (en) | 2015-08-17 | 2016-08-16 | Lysobactin for use in the treatment of bovine mastitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018001531A2 true CO2018001531A2 (es) | 2018-07-10 |
Family
ID=53871958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0001531A CO2018001531A2 (es) | 2015-08-17 | 2018-02-16 | Lisobactina para su uso en el tratamiento de la mastitis bovina |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20180346518A1 (es) |
| EP (1) | EP3337494B1 (es) |
| JP (1) | JP6921805B2 (es) |
| KR (1) | KR20180040674A (es) |
| CN (1) | CN107921088B (es) |
| AR (1) | AR105728A1 (es) |
| AU (1) | AU2016310221B2 (es) |
| BR (1) | BR112018003150A2 (es) |
| CA (1) | CA2995648C (es) |
| CO (1) | CO2018001531A2 (es) |
| CR (1) | CR20180110A (es) |
| DK (1) | DK3337494T3 (es) |
| ES (1) | ES2788734T3 (es) |
| HR (1) | HRP20200427T1 (es) |
| HU (1) | HUE048864T2 (es) |
| IL (1) | IL257342A (es) |
| LT (1) | LT3337494T (es) |
| MX (1) | MX2018002020A (es) |
| PE (1) | PE20180574A1 (es) |
| PH (1) | PH12018500339A1 (es) |
| PL (1) | PL3337494T3 (es) |
| PT (1) | PT3337494T (es) |
| RU (1) | RU2741764C2 (es) |
| SI (1) | SI3337494T1 (es) |
| TW (1) | TW201717991A (es) |
| WO (1) | WO2017029271A1 (es) |
| ZA (1) | ZA201801788B (es) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1266247A (en) | 1985-03-25 | 1990-02-27 | Adrienne A. Tymiak | Antibiotic prepared from lysobacter sp. sc 14,067 |
| JPH01132600A (ja) | 1987-11-17 | 1989-05-25 | Shionogi & Co Ltd | カタノシンａおよびｂならびにその製造法 |
| DE10320781A1 (de) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | Acylierte Nonadepsipeptide |
| DE102004051023A1 (de) | 2004-10-20 | 2006-05-04 | Bayer Healthcare Ag | Desoxo-Nonadepsipeptide |
| DE102004051024A1 (de) | 2004-10-20 | 2006-04-27 | Bayer Healthcare Ag | Heterocyclyl-substituierte Nonadepsipeptide |
| DE102004051025A1 (de) * | 2004-10-20 | 2006-04-27 | Bayer Healthcare Ag | Substituierte Nonadepsipeptide |
| DE102004053407A1 (de) | 2004-11-05 | 2006-05-11 | Bayer Healthcare Ag | Acylierte Nonadepsipeptide II |
| DE102004053410A1 (de) | 2004-11-05 | 2006-05-11 | Bayer Healthcare Ag | Cyclische Nonadepsipeptidamide |
| DE102004053409A1 (de) | 2004-11-05 | 2006-05-11 | Bayer Healthcare Ag | Verfahren zur gezielten Herstellung von Lysobactinfragmenten |
| DE102006003443A1 (de) | 2006-01-25 | 2007-07-26 | Aicuris Gmbh & Co. Kg | Asparagin-10-substituierte Nonadepsipeptide |
| DE102006018250A1 (de) | 2006-04-13 | 2007-10-18 | Aicuris Gmbh & Co. Kg | Verfahren zum Herstellen von cyclischen Depsipeptiden |
| DE102006018080A1 (de) * | 2006-04-13 | 2007-10-18 | Aicuris Gmbh & Co. Kg | Lysobactinamide |
-
2016
- 2016-08-15 TW TW105125886A patent/TW201717991A/zh unknown
- 2016-08-16 RU RU2018109421A patent/RU2741764C2/ru active
- 2016-08-16 BR BR112018003150-0A patent/BR112018003150A2/pt active Search and Examination
- 2016-08-16 HU HUE16757590A patent/HUE048864T2/hu unknown
- 2016-08-16 EP EP16757590.1A patent/EP3337494B1/en active Active
- 2016-08-16 CR CR20180110A patent/CR20180110A/es unknown
- 2016-08-16 CN CN201680048075.4A patent/CN107921088B/zh active Active
- 2016-08-16 DK DK16757590.1T patent/DK3337494T3/da active
- 2016-08-16 US US15/752,936 patent/US20180346518A1/en not_active Abandoned
- 2016-08-16 KR KR1020187007351A patent/KR20180040674A/ko not_active Application Discontinuation
- 2016-08-16 ES ES16757590T patent/ES2788734T3/es active Active
- 2016-08-16 PL PL16757590T patent/PL3337494T3/pl unknown
- 2016-08-16 PE PE2018000260A patent/PE20180574A1/es not_active Application Discontinuation
- 2016-08-16 MX MX2018002020A patent/MX2018002020A/es unknown
- 2016-08-16 CA CA2995648A patent/CA2995648C/en active Active
- 2016-08-16 AU AU2016310221A patent/AU2016310221B2/en active Active
- 2016-08-16 PT PT167575901T patent/PT3337494T/pt unknown
- 2016-08-16 SI SI201630691T patent/SI3337494T1/sl unknown
- 2016-08-16 WO PCT/EP2016/069380 patent/WO2017029271A1/en active Application Filing
- 2016-08-16 LT LTEP16757590.1T patent/LT3337494T/lt unknown
- 2016-08-16 JP JP2018508195A patent/JP6921805B2/ja active Active
- 2016-08-17 AR ARP160102525A patent/AR105728A1/es unknown
-
2018
- 2018-02-04 IL IL257342A patent/IL257342A/en unknown
- 2018-02-14 PH PH12018500339A patent/PH12018500339A1/en unknown
- 2018-02-16 CO CONC2018/0001531A patent/CO2018001531A2/es unknown
- 2018-03-16 ZA ZA201801788A patent/ZA201801788B/en unknown
-
2020
- 2020-03-16 HR HRP20200427TT patent/HRP20200427T1/hr unknown
-
2022
- 2022-06-06 US US17/832,868 patent/US20230125394A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019005379A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| MX361590B (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| CL2016000008A1 (es) | Tratamiento de lesiones inflamatorias de rosacea con ivermectina. | |
| IN2013MU03583A (es) | ||
| BR112017026294A2 (pt) | formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição. | |
| BR112016001544A2 (pt) | composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas | |
| IN2013MU00711A (es) | ||
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| MX340985B (es) | Compuestos de n-heteroarilo. | |
| AR101674A1 (es) | Uso de un compuesto tricíclico que contiene nitrógeno | |
| CO2016003340A2 (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| MY179605A (en) | Use of benzimidazole-proline derivatives | |
| PH12016500946A1 (en) | Composition for preventing and curing mycoplasma infection | |
| BR112015023481A2 (pt) | composição de lipossoma de liberação controlada de fármaco | |
| WO2015001163A3 (es) | Nanopartículas lipídicas para la cicatrización de heridas | |
| EA201592040A1 (ru) | Иммуногенная композиция для применения в терапии | |
| BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer | |
| MX2020000009A (es) | Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos. | |
| MX361808B (es) | Derivados de tilosina y metodo para su preparacion. | |
| CO2018001531A2 (es) | Lisobactina para su uso en el tratamiento de la mastitis bovina | |
| PH12014501601A1 (en) | Artemisinin-based combination therapy for treating viral mediated disease |